IceCure's ProSense® Shows High Effectiveness in Alleviating Endometriosis Pain

IceCure's ProSense® and Its Impact on Abdominal Wall Endometriosis

In an exciting development for women suffering from abdominal wall endometriosis (AWE), IceCure Medical Ltd. has shared noteworthy results from an independent study on its ProSense® cryoablation technology. AWE is a painful condition that can arise post-surgery, typically after cesarean sections. This debilitating ailment is characterized by chronic pain and the presence of a palpable mass that can severely compromise a woman's quality of life. Traditional treatment methods like hormonal therapies and surgical interventions often come with significant downsides, making non-invasive options increasingly desirable.

The study, published in the Journal of Personalized Medicine, examined 14 female patients with a total of 23 lesions and aimed to assess the efficacy and safety of the ProSense® system between September 2022 and April 2025 at the Nîmes University Hospital in France. Results revealed a significant reduction in pain levels, with median pain scores plummeting from 8 to 0 at the three-month follow-up mark, a staggering achievement that underscores the treatment's potential for effective pain management.

Chief Executive Officer Eyal Shamir expressed optimism about the findings, noting, "We are very pleased to share these results, which indicate that percutaneous cryoablation with ProSense® is a safe and efficient method for treating AWE. The procedure not only brings substantial pain relief but also yields excellent cosmetic outcomes."

Key Findings from the Study

The study provides several key takeaways regarding the ProSense® procedure:
1. Substantial Pain Relief: Patients reported a drastic drop in pain levels, thus marking a positive shift in their overall well-being.
2. High Procedural Efficacy: MRI examinations confirmed complete ablation zone coverage, and all lesions displayed disappearance of any associated bleeding.
3. Streamlined Procedure: The treatment was performed with impressive median times of only 15 minutes for the ablation itself and 93 minutes for the overall procedure.
4. Safe Outcomes: Notably, there were no reported complications or visible scarring post-procedure, which is a common concern for patients undergoing traditional surgeries.
5. Low Retreat Rate: Only 14% of patients required a second treatment, both of which led to satisfactory results.

Addressing a Global Concern

According to the World Health Organization, endometriosis affects approximately 10% of women of reproductive age, equating to around 190 million individuals worldwide. This chronic condition often brings with it severe life-altering symptoms, making effective treatment methods all the more crucial.

The ProSense® Cryoablation System stands out as a game-changer in the landscape of endometriosis management. Its novel use of liquid nitrogen enables it to create substantial lethal zones for effective treatment across various tumor types, including breast, kidney, lung, and liver lesions. By facilitating quicker recoveries, less pain, and reduced risks of complications, ProSense® allows for efficiency in outpatient settings, making treatments more accessible.

IceCure Medical's Vision

Founded in Israel, IceCure Medical is focused on innovating and advancing cryoablation therapies that offer alternative solutions to invasive surgeries for both benign and malignant tumors. With the ProSense® system gaining FDA clearance and approval in the European Union for gynecological indications, its commercial potential appears to be on the rise, along with increased interest from medical professionals in offering such minimally invasive options to patients.

In closing, as IceCure Medical continues its commitment to improving women's healthcare through innovative treatments, the findings from this study herald a promising future for those battling the challenges of endometriosis. As healthcare providers begin to incorporate ProSense® into their practices, many women may soon find the relief they desperately need, positioning IceCure Medical as a leader in the field of cryoablation therapy.